Pfizer beats Street 2Q forecasts despite big drop in profit

Rising sales of Pfizer Inc.'s key new medicines and prospects more drugs will be approved over the next couple years have analysts speculating the biggest U.S. drugmaker won't break up after all.

For the past five years, the maker of Viagra and fibromyalgia and pain treatment Lyrica has been mulling a split up that might enable the resulting pieces to grow faster.

Pfizer beats Street 2Q forecasts despite big drop in profit